OverT Bio Raises $16 Million, Tapping Innovative Reprogramming of Immune Cells to Deliver Next-Generation Therapies

NEW YORK--(BUSINESS WIRE)--OverT Bio, a data-driven company working to unlock the curative potential of cell therapies in solid tumors, announced today that it has raised $16 million in seed funding. The round was co-led by ARTIS Ventures and Wing VC, with participation from Fusion Fund, OMX Ventures, Alexandria Venture Investments, Gaingels, Civilization Ventures, Hawktail, and Cancer Research Institute. The funding will go toward expanding discovery platforms focused on addressing the primary